• Machine Learning-Driven Prediction of LNPs for mRNA Vaccines

  2026-05-09

  This study introduces a machine learning model, LightGBM, to predict optimal lipid nanoparticle (LNP) formulations for mRNA vaccine delivery, accelerating the traditionally resource-intensive screening of ionizable lipids such as SM-102 and DLin-MC3-DMA. The approach demonstrates strong predictive accuracy and experimental validation, offering a scalable alternative for rational LNP design in vaccine development.

• G-1 (CAS 881639-98-1): Unlocking GPR30 in Neuropathic Pain M

  2026-05-09

  Explore the unique role of G-1, a selective GPR30 agonist, in advancing neuropathic pain research. This article uncovers novel mechanistic insights and assay considerations that set it apart from prior reviews.

• Neuroligin 1 Loss in Striatal D2-MSNs Drives Repetitive Beha

  2026-05-08

  This study identifies Neuroligin 1 (NLGN1) deficiency in striatal D2 receptor-expressing medium spiny neurons (D2-MSNs) as a driver of excessive repetitive behaviors in mice, mediated via PKC overactivation. The findings clarify cellular and molecular mechanisms underlying autism-related restricted, repetitive behaviors, highlighting new potential intervention targets.

• Pifithrin-α: Applied p53 Inhibition for Ferroptosis & Neurop

  2026-05-07

  Pifithrin-α (PFTα) empowers researchers to precisely modulate p53-dependent apoptosis and ferroptosis, unlocking advanced neuroprotection and cell cycle arrest studies. Leveraging new findings on p53-mediated ferroptosis and cognitive dysfunction, this guide delivers actionable workflows, troubleshooting insights, and comparative strategies for maximizing experimental reproducibility.

• Phebestin and Bestatin: Aminopeptidase Inhibitors in Malaria

  2026-05-07

  This article examines a recent study evaluating phebestin, a bestatin-related aminopeptidase inhibitor, for its potent antiplasmodial activity against resistant malaria strains. The findings illustrate how targeted inhibition of parasite aminopeptidases can disrupt Plasmodium survival and inform new directions in antimalarial drug development.

• Pam3CSK4 as a TLR1/2 Agonist: Advanced Workflow Applications

  2026-05-06

  Pam3CSK4 delivers reproducible TLR1/2 activation, enabling precision modeling of innate immune responses and allergy modulation. This guide translates the latest neuro-immune insights and offers step-by-step protocols, troubleshooting, and real-world optimization tips for bench scientists.

• Z-VEID-FMK: Selective Caspase-6 Inhibitor for Apoptosis Assa

  2026-05-06

  Z-VEID-FMK is a potent, cell-permeable caspase-6 inhibitor widely used in apoptosis and neuronal cell death research. Its irreversible, covalent action enables precise blockade of caspase-6 activity, making it essential for dissecting caspase-dependent pathways in disease models. This article details its mechanism, protocol parameters, and evidence base.

• Machine Learning Prediction of Lipid Nanoparticles for mRNA

  2026-05-05

  This study presents a machine learning approach to predict the efficacy of lipid nanoparticle (LNP) formulations for mRNA vaccine delivery. By integrating LightGBM modeling with molecular dynamics, the research identifies critical ionizable lipid substructures and validates computational predictions with in vivo data, offering a promising framework for rational LNP design in mRNA vaccine development.

• GRA12: A Conserved Toxoplasma Virulence Factor via In Vivo C

  2026-05-05

  This study identified GRA12 as a key, conserved virulence factor in Toxoplasma gondii using systematic in vivo CRISPR-Cas9 screens, revealing its cross-strain and cross-host importance for acute infection survival. The findings clarify how GRA12 protects the parasite from immune clearance, offering a new perspective for targeting universal virulence mechanisms.

• Translational Power of SM-102: Mechanisms and Optimization i

  2026-05-04

  This thought-leadership article explores the mechanistic role and translational potential of SM-102 (heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate) in mRNA vaccine delivery. By synthesizing experimental evidence, computational advances, and workflow insights, we provide actionable strategies for researchers aiming to optimize lipid nanoparticle (LNP) systems for clinical and preclinical success. The discussion contextualizes SM-102 within the broader competitive landscape, guided by the latest machine learning-driven design and real-world application scenarios, and highlights how APExBIO’s SM-102 transcends conventional product narratives to offer a robust, reproducible foundation for next-generation mRNA therapeutics.

• Alfuzosin HCl in BPH Research: Protocols, Innovations, and T

  2026-05-04

  Alfuzosin HCl's functionally uroselective α1 adrenoceptor antagonism, robust solubility, and favorable safety profile make it a benchmark compound for lower urinary tract research. This guide translates cutting-edge gastroretentive delivery innovations and experimental workflows into actionable, evidence-based protocols for optimized use in benign prostatic hyperplasia (BPH) studies.

• CDK9 Inhibitor (A3294): Technical Guidance and Protocols

  2026-05-03

  The CDK9 inhibitor (A3294) provides researchers with a selective, non-cytotoxic tool for investigating transcription elongation inhibition and HIV-1 propagation mechanisms. It is optimal for studies requiring precise cyclin dependent kinase 9 targeting, but is not suitable for pan-CDK inhibition or protocols needing prolonged stock solution storage.

• Thermal Shift Assays Reveal Ligands for Bacterial Sensor Pro

  2026-05-02

  This review synthesizes a decade of progress using thermal shift assays (TSAs) to identify ligands for bacterial sensor proteins. The article details methodological advances, reliability considerations, and the implications for functional genomics and pathway analysis.

• Novobiocin: Multi-Pathway Mechanisms and Translational Value

  2026-05-02

  Explore the multifaceted mechanisms of Novobiocin, a leading aminocoumarin antibiotic, and how its unique biochemical actions inform advanced assay design and translational workflows. This article delivers new practical and scientific insights distinct from standard resistance or protocol guides.

• IGF2BP3–FZD1/7 Axis Drives Carboplatin Resistance in TNBC

  2026-05-01

  This study uncovers how the m6A reader IGF2BP3 enhances stem-like properties and carboplatin resistance in triple-negative breast cancer (TNBC) by stabilizing FZD1/7 transcripts and activating β-catenin signaling. Targeting this axis—either genetically or pharmacologically—sensitizes cancer stem-like cells to carboplatin, offering a mechanistically justified therapeutic vulnerability with translational significance.

16530 records 1/1102 page Next 12345 下5页 Last page